Clinical Trial Update: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) [EARLY_Phase 1]

View source ↗

Summary

A first-in-human Phase 1 dose-escalation study of DT-7012, a CCR8-targeting monoclonal antibody from Domain Therapeutics, in relapsed or refractory cutaneous T-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• DT-7012 (anti-CCR8 monoclonal antibody)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | EARLY_Phase 1 | Status: NOT_YET_RECRUITING